Merck Q2 2026: Revenue Beats, Guidance Raised, but GAAP Loss on Terns Charge; Keytruda and Winrevair Drive Growth
MRK sits 66% above its 52-week low of $77.58.
Summary
Merck's Q2 2026 revenue of $16.6 billion beat expectations and full-year guidance was raised. A GAAP loss from acquisition accounting masks strong underlying performance led by Keytruda and Winrevair. The IRS dispute and upcoming generic headwinds are key risks.
Key Events · Earnings and Guidance · MRK
-
Q2 Revenue Beats, Guidance Raised
Revenue of $16.6 billion grew 5% year-over-year, driven by oncology and cardiometabolic products. Full-year 2026 sales guidance was raised, signaling confidence in the growth trajectory.
-
GAAP Loss Masks Strong Operations
The $1.335 billion GAAP net loss ($0.54 per share) was entirely due to a $5.7 billion non-cash R&D charge from the Terns acquisition. Excluding this and other items, non-GAAP EPS was a loss of $0.13, reflecting heavy investment but solid underlying profitability.
-
Keytruda and Winrevair Power Growth
Keytruda/Keytruda Qlex combined sales reached $8.4 billion (+5%), while Winrevair sales surged 75% to $588 million. Welireg also grew 67% to $271 million, demonstrating pipeline momentum.
-
IRS Dispute Over $1.3 Billion in Taxes
The IRS proposed adjustments to Merck's 2017-2018 transition tax, seeking an additional $1.3 billion plus $260 million in penalties. Merck is contesting, but an adverse outcome could be material.
Analysis · MRK · Life Sciences
A strong operational quarter pushed revenue to $16.6 billion, up 5%, and prompted a raise in the full-year sales outlook. The reported GAAP net loss of $1.335 billion stems entirely from a $5.7 billion non-cash R&D charge tied to the Terns acquisition—an accounting item that obscures underlying profitability. Combined Keytruda/Keytruda Qlex sales grew 5% to $8.4 billion, while Winrevair continued its rapid launch trajectory, surging 75% to $588 million. The balance sheet reflects $14.6 billion in acquisition spending, with cash and investments falling to $8.4 billion. A material contingent liability looms from the IRS dispute over $1.3 billion in proposed transition tax adjustments. Future revenue will face pressure from the loss of exclusivity for Januvia/Janumet and Bridion, but the pipeline is delivering—Lipfendra and multiple Keytruda label expansions were approved. This filing confirms the company is successfully navigating the post-Keytruda LOE transition, though the IRS matter and generic erosion warrant close attention.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRK was trading at $128.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $317.6B. The 52-week trading range was $77.58 to $135.05. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.